UG HEALTHCARE CORPORATIONLTD (8K7) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of UG HEALTHCARE CORPORATIONLTD S$0.04, price S$0.08, upside -46.1%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch UG HEALTHCARE CORPORATIONLTD for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
UG Healthcare Corporation Limited, an investment holding company, manufactures and sells disposable gloves. It operates through Latex Examination Gloves, Nitrile Examination Gloves, and Other Ancillary Products segments.
Show more
UG Healthcare Corporation Limited, an investment holding company, manufactures and sells disposable gloves. It operates through Latex Examination Gloves, Nitrile Examination Gloves, and Other Ancillary Products segments. The company distributes ancillary products, including surgical, vinyl, and cleanroom disposable gloves and reusable gloves, as well as face masks, and other medical disposables. It serves customers under the Unigloves brand name in Europe, North America, South America, Africa, Asia, and internationally. UG Healthcare Corporation Limited was founded in 1989 and is based in Singapore.
Stock analysis
UG HEALTHCARE CORPORATIONLTD (8K7) currently trades at 0.0760 SGD, while our model-based Fair Value estimate is 0.0410 SGD, 46.1% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 93/100, which puts the evidence level at low.
Scenario range: 0.0258 SGD (bear) to 0.0486 SGD (bull), the price of 0.0760 SGD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
UG HEALTHCARE CORPORATIONLTD reported revenue of 144M SGD in FY2025 versus 338M SGD in FY2021, a compound −19.2%/yr. Reported net income was −3.8M SGD in FY2025.
Key figures
Market cap 47.4M SGD (≈ $37.0M) · P/S ratio 0.33 · EPS (TTM) −0.0100 SGD · Net margin −2.6% · Return on equity −2.5% · Return on assets (EBIT) 12.3% · Operating margin −0.2% · Revenue (TTM) 146M SGD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −38% fair-value upside, at −46%, 8K7 screens richer than that median.
Fair Value models
Bear 0.0258 SGDFair Value 0.0410 SGDBull 0.0486 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.11/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+25.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.0%
Start year 2020 (pandemic). Over 10 years: +10.0% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
13.1% (2020) → −0.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare UG HEALTHCARE CORPORATIONLTD with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 189 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−46.1% · Below median
Profitability
Return on assets−0.5% · Bottom 25%
Net margin (TTM)−3.0% · Bottom 25%
Operating margin (TTM)−0.2% · Bottom 25%
Growth and dividend
Revenue growth2.8% · Below median
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B0.23× · Cheapest 25%
P/S (TTM)0.25× · Cheapest 25%
EV/EBITDA13.3× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)14· sector 33
PAST (return on equity)0· sector 28
HEALTH (low debt)93· sector 96
DIVIDEND (yield)0· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is UG HEALTHCARE CORPORATIONLTD (8K7) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 0.0410 SGD versus a price of 0.0760 SGD, about −46% upside (overvalued).
What is the fair value of 8K7?
Our model-based fair value for UG HEALTHCARE CORPORATIONLTD is 0.0410 SGD (as of Sep 27, 2026), built from audited fundamentals. The current price: 0.0760 SGD.
What is the quality score of 8K7?
UG HEALTHCARE CORPORATIONLTD has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for UG HEALTHCARE CORPORATIONLTD (8K7)?
Our model-based price target is the fair value of 0.0410 SGD (as of Sep 27, 2026) from 2 valuation models. Cautious scenario 0.0258 SGD, optimistic scenario 0.0486 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the UG HEALTHCARE CORPORATIONLTD stock forecast for 2026?
Our models put fair value at 0.0410 SGD, about −46% upside versus a price of 0.0760 SGD (overvalued). Cautious scenario 0.0258 SGD, optimistic scenario 0.0486 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of UG HEALTHCARE CORPORATIONLTD (8K7)?
UG HEALTHCARE CORPORATIONLTD reported trailing-twelve-month revenue of about 146M SGD (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of UG HEALTHCARE CORPORATIONLTD (8K7)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For UG HEALTHCARE CORPORATIONLTD it is 0.0410 SGD per share (as of Sep 27, 2026), against a price of 0.0760 SGD. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is UG HEALTHCARE CORPORATIONLTD stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 8K7 trades above its calculated fair value: price 0.0760 SGD, fair value 0.0410 SGD, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8K7?
No. The price is what the market pays today (0.0760 SGD); the fair value is what the company's own numbers justify (0.0410 SGD). For UG HEALTHCARE CORPORATIONLTD the two are 0.0350 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is UG HEALTHCARE CORPORATIONLTD worth?
The market values UG HEALTHCARE CORPORATIONLTD at about 47.4M SGD (market capitalisation, as of Sep 27, 2026). Per share that is 0.0760 SGD; our models calculate a fair value of 0.0410 SGD per share.
What do the bullish and bearish scenarios say about 8K7?
Our models span a range for UG HEALTHCARE CORPORATIONLTD: cautious scenario 0.0258 SGD, base 0.0410 SGD, optimistic 0.0486 SGD per share (as of Sep 27, 2026, price 0.0760 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of UG HEALTHCARE CORPORATIONLTD (8K7)?
Balance-sheet figures for UG HEALTHCARE CORPORATIONLTD (as of Sep 27, 2026): return on equity −2.5%, debt of 0.14 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 8K7 from its 52-week high?
UG HEALTHCARE CORPORATIONLTD trades at 0.0760 SGD, about 31% below its 52-week high of 0.1100 SGD and 9% above the low of 0.0700 SGD (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0410 SGD is for.
Which stocks are comparable to UG HEALTHCARE CORPORATIONLTD?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is UG HEALTHCARE CORPORATIONLTD stock attractive at the current price?
The data as of Sep 27, 2026: price 0.0760 SGD, calculated fair value 0.0410 SGD (−46%), Quality Score 54/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8K7 calculated?
We run UG HEALTHCARE CORPORATIONLTD through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0410 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. UG HEALTHCARE CORPORATIONLTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of UG HEALTHCARE CORPORATIONLTD (8K7)?
The closing price on Oct 1, 2026 was 0.0760 SGD. Our model-based fair value is 0.0410 SGD, about −46% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with UG HEALTHCARE CORPORATIONLTD right now?
The price sits above even our optimistic bull case (0.0486 SGD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (0.0258 SGD to 0.0486 SGD) leaves room in how you read the outcome.
Key figures of UG HEALTHCARE CORPORATIONLTD
How large is the market capitalisation of UG HEALTHCARE CORPORATIONLTD (8K7)?
The market capitalisation of UG HEALTHCARE CORPORATIONLTD is 47.4M SGD (≈ $37.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of UG HEALTHCARE CORPORATIONLTD (8K7)?
The price-to-sales ratio of UG HEALTHCARE CORPORATIONLTD is 0.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of UG HEALTHCARE CORPORATIONLTD (8K7)?
Earnings per share at UG HEALTHCARE CORPORATIONLTD are −0.0100 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of UG HEALTHCARE CORPORATIONLTD (8K7)?
The net margin of UG HEALTHCARE CORPORATIONLTD is −2.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of UG HEALTHCARE CORPORATIONLTD (8K7)?
The return on equity (ROE) of UG HEALTHCARE CORPORATIONLTD is −2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of UG HEALTHCARE CORPORATIONLTD (8K7)?
On an EBIT basis the return on assets of UG HEALTHCARE CORPORATIONLTD is 12.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of UG HEALTHCARE CORPORATIONLTD (8K7)?
The operating margin of UG HEALTHCARE CORPORATIONLTD is −0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at UG HEALTHCARE CORPORATIONLTD (8K7)?
Revenue at UG HEALTHCARE CORPORATIONLTD is growing +2.8% versus a year earlier (3y avg −14.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at UG HEALTHCARE CORPORATIONLTD (8K7)?
Earnings per share at UG HEALTHCARE CORPORATIONLTD are growing −83.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does UG HEALTHCARE CORPORATIONLTD (8K7) generate?
The free cash flow of UG HEALTHCARE CORPORATIONLTD is −8.1M SGD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does UG HEALTHCARE CORPORATIONLTD (8K7) carry?
The net debt of UG HEALTHCARE CORPORATIONLTD is 23.5M SGD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch UG HEALTHCARE CORPORATIONLTD in the live analysis
One click puts UG HEALTHCARE CORPORATIONLTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
